• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Citalopram Safety Warning Has Serious Consequences for VA Patients

Citalopram Safety Warning Has Serious Consequences for VA Patients

July 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
bret-a-moore-psyd-abppBret A. Moore, PsyD, ABPP Board-Certified Clinical Psychologist, San Antonio, TX Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Subject: (Rector T et al, Am J Psychiatry, 2016; ahead of publication)

Short Description: In the summer of 2011, the Food and Drug Administration (FDA) reported that post-marketing surveillance showed that patients taking greater than 40 mg/day of citalopram were at greater risk of QT prolongation. The agency advised doctors not to prescribe doses higher than 40 mg/day, and no higher than 20 mg/day in the elderly. Shortly thereafter, the Department of Veterans Affairs (VA) alerted its providers to this warning. VA researchers recently published a study detailing the results of this warning on patients.

A search of the VA national electronic health records found that in August 2011, shortly after the FDA issued the warning, 35,848 patients had a prescription higher than 40 mg/day of citalopram, with an average dose of 64 mg/day. Although VA clinicians were not required to decrease doses after the warning, many did. Within six months of the warning, 60% of the high-dose patients had been prescribed doses of 40 mg/day or less. The researchers compared rates of hospitalizations and mortality in patients whose dose was decreased vs. those who continued on high-dose citalopram.

Hospitalization or death for any reason was 2.5 times greater in the reduced-dose group vs. the maintained-dose group. Depression-related hospitalizations were also higher in the reduced-dose group, as was self-injurious behavior. Interestingly, reducing the dose did not do anything obvious to prevent arrhythmia—there was no drop in hospitalization for cardiac arrhythmias. The researchers concluded that the FDA warning did more harm than good.

TCPR’s Take: If you have patients who are doing well on high-dose citalopram, don’t reduce the dose just based on the FDA warning. Instead, check an EKG, and if there is a prolonged QT interval, consult with a cardiologist to determine whether the risk of an arrhythmia is high enough to justify slashing the dose of an antidepressant. Judging by the results of this study, you may ultimately decide to stay the course.
General Psychiatry
KEYWORDS depression research-update
    Bret a moore psyd abpp
    Bret A. Moore, PsyD, ABPP

    Extended-Release Guanfacine Improves ADHD Symptoms in Autism

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2016
    SUBSCRIBE NOW
    Table Of Contents
    Metoclopramide Helps Clozapine-Related Drooling
    N-acetylcysteine Shows Promise for Skin-Picking Disorder
    Buprenorphine for Suicidality? Maybe
    Citalopram Safety Warning Has Serious Consequences for VA Patients
    Take The CME Test For Medication in Pregnancy, TCPR, July/August 2016
    How to Evaluate and Treat Mood Disorders in Pregnancy
    What’s New with the FDA Labeling for Pregnancy and Lactation?
    Assessing Illness and Medication Treatment in the Perinatal Period
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.